In this morning’s readout from Novo's phase 2 trial of monlunabant in 243 people with obesity and metabolic syndrome, it ...

Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...

Masimo’s long-running proxy fight has come to a close, at least for now. | Masimo’s long-running proxy fight has come to a ...

Warren Biddle hit the exit from his role as SVP, global head of commercial at Gilead’s CAR-T unit Kite Pharma to take on the ...

Edgewise Therapeutics's hypertrophic cardiomyopathy (HCM) asset has started off with a bang after early safety data sent the ...

A surgeon makes small incisions in the eye, sucks out the cloudy lens and replaces it with an artificial lens implant.

The fall flurry of biotech IPOs shows no signs of abating, with Upstream Bio becoming the latest company to express an ...

With COVID-19 still spreading and mpox emerging as a public health emergency of international concern, the National ...

Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to ...

Slow enrollment in a key clinical trial has driven Genfit to rework the protocol to try to keep the study on track. | Slow ...

Achilles Therapeutics has torn up its strategy. The British biotech is stopping work on its clinical-phase cell therapy, ...

Vanda Pharmaceuticals has failed to persuade the FDA to approve its gastroparesis candidate on the strength of a phase 3 ...